ST Innovative diagnostics’ team of renowned Hemato-Oncology & Molecular Biology experts from Rabin Medical Center & Tel-Aviv University, Israel, collaborated to reach a significant breakthrough in non-invasive detection and real-time, frequent monitoring of Cancer progression.

Our Mission
Provide a Robust, Easily-implementable, Real-time, Cancer Progression and Treatment Response Monitoring Test.Â
Our Journey
For 14 years, Dr. Esther Rabizadeh (Ph.D.), our company founder & CSO, led a pioneering research at Rabin Medical Center and Tel Aviv University, aimed at developing a real-time, robust blood test for cancer monitoring & early detection.
​
The resulting breakthrough technology, based on Fibrinogen Like Protein 2 (FGL2) activity in platelets, shows high Accuracy, Sensitivity & Specificity in clinical studies in Lymphoma, followed by Lung-Cancer, Colon & Prostate Cancers as well as Cutaneous T-Cell Lymphoma.
Our Assay is protected by 7 patents across the US, Europe, China, Hong Kong, and Israel.
​​
We further aim to construct a comprehensive FGL2 baseline profiling database, utilizing AI-derived profile correlations to develop a predictive model and position our assay as a routine screening test for early cancer detection.

LEADERSHIP
DR. ESTHER RABIZADEH, PHD
Founder & CSO
Dr. Esther Rabizadeh is a highly accomplished expert in the fields of hemato-oncology and cell biology. With a distinguished career spanning decades, she served as the Managing Director of Hematology Laboratories at Rabin Medical Center and headed the Hemato-Oncology research team at the Felsenstein Medical Research Center (FMRC), Tel-Aviv University.
Dr. Rabizadeh's research contributions have been published in prestigious journals, including the Journal of Cancer Research Clinical Oncology, Cancer Research, Clinical Research, Experiment Oncology, and PLOS One, solidifying her reputation as an influential figure in her field.
Her recent focus the activity of Fibrinogen Like Protein 2 (FGL2) in malignancies, culminated in the creation of a revolutionary non-invasive predictive blood biomarker. This biomarker proficiently tracks malignancies and exhibits a robust correlation with PET/CT imaging.
​
Dr. Rabizadeh's remarkable work has led to impactful publications and the acquisition of patents in the United States, Europe, China, HK and Israel, demonstrating her significant contributions to cancer research and patient care.


SHEILA ALTMAN, LLB, MBA
CEO
A seasoned business manager and strategist, with a track record of growing businesses & products, through a unique blend of technological, business, and legal proficiencies within C-Level roles.
​
Sheila has over 15 years of experience in multinational corporates as well as startups, leading product, business & corporate growth strategies.
Sheila holds a Law degree from Tel-Aviv University, complemented by a MBA from Reichman University and is a member of the Israeli Bar since 2000.
SCIENTIFIC & MEDICAL ADVISORY
MARKET AND REGULATORY ADVISORY

Supported by:
KEY OPINION LEADERS & ESTEEMED CLINICIANS
CLINICIANS
Rabin Medical Center, Petah Tikva
Prof. Anat Gafter-Gvili, MD
Prof. Ronit Gurion, MD
Ichilov Medical Center
​Prof. Ravit Geva, MD​
Shaarei tzedek Medical Center, Jerusalem
Prof. Yishai Ophran, MD
Rambam Medical Center, Haifa
Dr. Shimrit Ringelstein Harlev , MD
Meir Medical Center, Kfar Saba
Dr. Gilad Itzhaki, MD
Wolfson Medical Center, Holon
Prof. Ronen Brenner, MD
Soroka Medical Center, Beer Sheva
Dr. Itai Levi
Key Opinion Leaders (KOLs )
Prof. Jonathan Friedberg, M.D Prof. Jakobe Rowe, M.D
Prof. Nir Peled, MD
​




